"The current strategy is to build value into the Deoxymab...

"The current strategy is to build value into the Deoxymab program through pre-clinical activities, and to seek to partner or fund through non-dilutive sources the costly clinical development programs for the Company’s IgM assets."

"The Company has completed an investigation into the fundamental issues that arose with the manufacturing of PAT-SM6 antibody, and has identified a path forward to restart the development of PAT-SM6 and its other IgM assets. Given the significant cost and time involved with these programs Patrys will only consider reactivation on a partnered, risk sharing basis or if non-dilutive funds can be accessed."

Well-said. The current strategy is reasonable and in the right direction.

However, it might need to be emphasised that the reactivation of PAT-SM6 clinical trial should be regarded as equally important as the development of Deoxymab assets.

Actually, around the globe, there are many big biotech companies looking for early stage novel antibody-based cancer therapies such as PAT-SM6, and for those companies money is not an issue at all.

Once non-dilutive funds for PAT-SM6 development are secured, the fundamentals and prospects of this stock will be greatly improved, and the strategic risks facing the company will be significantly alleviated.

It is an old saying that it is easier said than done, but as another old and true saying goes, where there's a will, there's a way.

In view of the big picture, the game of Deoxymab 3E10 and related rights issue being played should not be a factor against that will.

Hurry up and don't wait.